John W. Strohbehn Distinguished Professor of Biomedical Engineering
Appointments and Affiliations
- John W. Strohbehn Distinguished Professor of Biomedical Engineering
- Professor of Biomedical Engineering
- Associate Professor of Surgery
- Associate Professor in Orthopaedic Surgery
- Associate Professor in Cell Biology
- Associate of the Duke Initiative for Science & Society
- Core Faculty in Innovation & Entrepreneurship
- Member of the Duke Cancer Institute
- Affiliate of the Duke Regeneration Center
- Office Location: 2123 CIEMAS, Durham, NC 27708
- Office Phone: (919) 613-2147
- Email Address: email@example.com
- B.S. Georgia Institute of Technology, 2001
- Ph.D. Georgia Institute of Technology, 2006
Research InterestsGene therapy, genomics and epigenomics, biomolecular and cellular engineering, regenerative medicine, and synthetic biology.
- BME 493: Projects in Biomedical Engineering (GE)
- BME 494: Projects in Biomedical Engineering (GE)
- BME 562: Biology by Design (GE, MC)
- BME 590L: Special Topics with Lab
- BME 791: Graduate Independent Study
- BME 792: Continuation of Graduate Independent Study
- BME 899: Special Readings in Biomedical Engineering
- CELLBIO 493: Research Independent Study
- EGR 393: Research Projects in Engineering
In the News
- Duke Awards 22 Distinguished Professorships (Jun 28, 2021)
- School of Medicine Faculty, Students Shine During Duke University Research Week…
- Using CRISPR Tagging to Turn Stem Cells Into Just the Adult Cell You Need (Dec …
- Taking Aim at the 'Dark' Genome to Uncover New Therapies for Disease (Oct 1, 20…
- New CRISPR Approach Expands the Genetic Engineering Toolkit (Sep 24, 2019 | Pra…
- Engineering 'Hairpins' Increases Accuracy of CRISPR Genome Editing (Apr 15, 201…
- Single Genetic Editing Treatment Provides Long-Term Benefits in Mice (Feb 18, 2…
- A Chinese Scientist Gene-Edited a Human Embryo: What, How & Why (Dec 17, 2018 |…
- From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
- CRISPR/Cas9 Silences Gene Associated with High Cholesterol (Apr 27, 2018)
- Pratt Researchers Advance Treatment That Reduces Blood Cholesterol Levels in Ad…
- Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
- Two Postdocs Win Gene Therapy Fellowship (Nov 29, 2017)
- Screening the Human Genome's 'Dark Matter' (Apr 4, 2017 | Pratt School of Engin…
- CRISPR Screen Detects Functional Gene Regulation (Apr 3, 2017 | The Scientist)
- Betting on the first disease to be treated by gene editing (Mar 15, 2017 | CNBC)
- Duke Awards Distinguished Professorships, Inducts New Bass Society Members (May…
- Gene editing treats disease in mice (Jan 4, 2016 | BBC News)
- Gene editing offers hope for treating Duchenne muscular dystrophy, studies find…
- CRISPR Treats Genetic Disorder in Adult Mammal (Dec 31, 2015)
- Pratt Research Brings Precise Control to Gene Expression (Oct 27, 2015)
- Studying the Harm and Healing Power of Steroids (May 26, 2015)
- Engineers gain control of gene activity; new therapies may be ahead (Apr 6, 201…
- Bacterial Defense Mechanism Targets Duchenne Muscular Dystrophy (Feb 19, 2015)
- Bacterial Defense Mechanism Targets Duchenne Muscular Dystrophy (Feb 18, 2015)
- Lighting Up the Duke 'D' With Genes (Feb 10, 2015)
- Black, Joshua B., Andrew F. Adler, Hong-Gang Wang, Anthony M. D’Ippolito, Hunter A. Hutchinson, Timothy E. Reddy, Geoffrey S. Pitt, Kam W. Leong, and Charles A. Gersbach. “Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells.” Cell Stem Cell 19, no. 3 (September 1, 2016): 406–14. https://doi.org/10.1016/j.stem.2016.07.001.
- Maeder, Morgan L., and Charles A. Gersbach. “Genome-editing Technologies for Gene and Cell Therapy.” Molecular Therapy : The Journal of the American Society of Gene Therapy 24, no. 3 (March 2016): 430–46. https://doi.org/10.1038/mt.2016.10.
- Thakore, Pratiksha I., Joshua B. Black, Isaac B. Hilton, and Charles A. Gersbach. “Editing the epigenome: technologies for programmable transcription and epigenetic modulation.” Nature Methods 13, no. 2 (February 2016): 127–37. https://doi.org/10.1038/nmeth.3733.
- Nelson, Christopher E., Chady H. Hakim, David G. Ousterout, Pratiksha I. Thakore, Eirik A. Moreb, Ruth M. Castellanos Rivera, Sarina Madhavan, et al. “In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.” Science 351, no. 6271 (January 22, 2016): 403–7. https://doi.org/10.1126/science.aad5143.
- Thakore, Pratiksha I., Anthony M. D’Ippolito, Lingyun Song, Alexias Safi, Nishkala K. Shivakumar, Ami M. Kabadi, Timothy E. Reddy, Gregory E. Crawford, and Charles A. Gersbach. “Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.” Nat Methods 12, no. 12 (December 2015): 1143–49. https://doi.org/10.1038/nmeth.3630.
- Hilton, Isaac B., Anthony M. D’Ippolito, Christopher M. Vockley, Pratiksha I. Thakore, Gregory E. Crawford, Timothy E. Reddy, and Charles A. Gersbach. “Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.” Nat Biotechnol 33, no. 5 (May 2015): 510–17. https://doi.org/10.1038/nbt.3199.
- Polstein, Lauren R., and Charles A. Gersbach. “A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.” Nature Chemical Biology 11, no. 3 (March 2015): 198–200. https://doi.org/10.1038/nchembio.1753.
- Ousterout, David G., Ami M. Kabadi, Pratiksha I. Thakore, William H. Majoros, Timothy E. Reddy, and Charles A. Gersbach. “Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.” Nat Commun 6 (February 18, 2015): 6244. https://doi.org/10.1038/ncomms7244.
- Perez-Pinera, Pablo, D Dewran Kocak, Christopher M. Vockley, Andrew F. Adler, Ami M. Kabadi, Lauren R. Polstein, Pratiksha I. Thakore, et al. “RNA-guided gene activation by CRISPR-Cas9-based transcription factors.” Nat Methods 10, no. 10 (October 2013): 973–76. https://doi.org/10.1038/nmeth.2600.